ArticleDiscover oncology2026
A prognostic nomogram integrating Epstein-Barr virus DNA and specific inflammatory indices for early recurrent or metastatic nasopharyngeal carcinoma after first-line nedaplatin-based therapy.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
purposeThis study developed and validated a nomogram integrating specific inflammatory and Epstein-Barr virus (EBV) DNA quantification to predict overall survival (OS) in patients with nasopharyngeal carcinoma (NPC) who experienced recurrence or metastasis within ten years after completing first-line treatment with nedaplatin.
methodsThe nomogram was constructed utilizing data from a retrospective cohort of 120 patients treated at The People's Hospital of Guangxi Zhuang Autonomous Region between January 2017 and December 2022. The predictive accuracy and clinical utility of the model were assessed through the concordance index (C-index), decision curve analysis (DCA), calibration plots, and time-dependent receiver operating characteristic (ROC) curves.
resultsMultivariate analysis revealed that an elevated albumin-to-globulin ratio (AGR) and lymphocyte-to-monocyte ratio (LMR) were significantly correlated with improved OS, whereas increased levels of alkaline phosphatase (ALP) and the presence of EBV DNA were associated with poorer prognostic outcomes. These four variables were integrated into a nomogram, which exhibited robust predictive accuracy, as evidenced by a C-index of 0.747 (95% CI, 0.689-0.805). This performance marked a substantial enhancement in discriminatory ability relative to the 8th edition UICC/AJCC staging system, which yielded a C-index of 0.566 (95% CI, 0.509-0.624). Additionally, the nomogram demonstrated satisfactory calibration, effectively stratified patients by risk (log-rank test, P < 0.001), and showed clinical applicability as confirmed through DCA.
conclusionsThis study successfully constructed a nomogram model for patients with NPC who experienced recurrence or metastasis within ten years following the completion of first-line treatment with nedaplatin. This model functions as an adjunct to the 8th edition UICC/AJCC staging system and provides significant support for clinical decision-making processes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.